Executives On The Move: Changes At AN2 Therapeutics, Cabaletta Bio And More
C-suite changes at Omega Therapeutics and promotions at Cabaletta Bio are among recent executive changes in the industry. Meanwhile, new directors were appointed at AN2 Therapeutics, among others.
Keep up with the top pharma business news of the week. On the go.
More from Executives On The Move
- • By
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
- • By
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
- • By
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.
- • By
<p>Executive Summary </p> <br> <p>Other recent moves in the industry include changes at the top at Adocia, CSL and Entrada Therapeutics.</p>
More from Leadership
- • By
Starboard Value has reportedly bought a $1bn stake in Pfizer with an ambition to turn the big pharma around. But growth, not cost cuts, are Pfizer’s challenge.
- • By
<p>Executive Summary </p> <br> <p>Other recent moves in the industry include changes at the top at Adocia, CSL and Entrada Therapeutics.</p>
- • By
<p>Executive Summary </p> <br> <p>Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements</p>
